Emma Bertucci

Dr. Emma Bertucci

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2019 in BioFactors
Verified
Journal Article
Closed access
PDF file
MZManuela Zavatti
Manuela Zavatti
FBFrancesca Beretti
Francesca Beretti
Francesca CasciaroFrancesca Casciaro
Francesca Casciaro
Emma BertucciEmma Bertucci
Emma Bertucci
Tullia MaraldiTullia Maraldi
Tullia Maraldi

2 January 2019 in The European Journal of Contraception & Reproductive Health Care
Verified
Journal Article
Closed access
GGGiovanni Grandi
Giovanni Grandi
Fabio BarraFabio Barra
Fabio Barra
Simone FerreroSimone Ferrero
Simone Ferrero
FSFilomena Giulia Sileo
Filomena Giulia Sileo
Emma BertucciEmma Bertucci
Emma Bertucci
FFFabio Facchinetti
Fabio Facchinetti
A systematic review was carried out of studies of women with endometriosis, to examine the evidence for efficacy of the use of hormonal contraception to improve disease-related pain and decrease postoperative risk of disease recurrence. A search of the Medline/PubMed and Embase databases was performed to identify all published English language studies on hormonal contraceptive therapies (combined hormonal contraceptives [CHCs], combined oral contraceptives [COCs], progestin-only pills [POPs] and progestin-only contraceptives [POCs]) in women with a validated endometriosis diagnosis, in comparison with placebo, comparator therapies or other hormonal therapies. Main outcome measures were endometriosis-related pain (dysmenorrhoea, pelvic pain and dyspareunia), quality of life (QoL) and postoperative rate of disease recurrence during treatment. CHC and POC treatments were associated with clinically significant reductions in dysmenorrhoea, often accompanied by reductions in non-cyclical pelvic pain and dyspareunia and an improvement in QoL. Only two COC preparations (ethinylestradiol [EE]/norethisterone acetate [NETA] and a flexible EE/drospirenone regimen) demonstrated significantly increased efficacy compared with placebo. Only three studies found that the postoperative use of COCs (EE/NETA, EE/desogestrel and EE/gestodene) reduced the risk of disease recurrence. There was no evidence that POCs reduced the risk of disease recurrence. CHCs and POCs are effective for the relief of endometriosis-related dysmenorrhoea, pelvic pain and dyspareunia, and improve QoL. Some COCs decreased the risk of disease recurrence after conservative surgery, but POCs did not. There is insufficient evidence, however, to reach definitive conclusions about the overall superiority of any particular hormonal contraceptive.

11 April 2007 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Closed access
PDF file
GFGuglielmina Fantuzzi
Guglielmina Fantuzzi
GAGabriella Aggazzotti
Gabriella Aggazzotti
Elena RighiElena Righi
Elena Righi
FFfabio Facchinetti
fabio Facchinetti
Emma BertucciEmma Bertucci
Emma Bertucci
SSSalvatore Sciacca
Salvatore Sciacca

22 January 2007 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
VMVincenzo Mazza
Vincenzo Mazza
MPMariangela Pati
Mariangela Pati
Emma BertucciEmma Bertucci
Emma Bertucci
CRClaudia Re
Claudia Re
ARAndrea Ranzi
Andrea Ranzi
AVAnnibale Volpe
Annibale Volpe

11 July 2020 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
FSFilomena Giulia Sileo
Filomena Giulia Sileo
DMDaniele Di Mascio
Daniele Di Mascio
Giuseppe RizzoGiuseppe Rizzo
Giuseppe Rizzo
MCMassimo Caulo
Massimo Caulo
LMLucia Manganaro
Lucia Manganaro
FDFrancesco D'Antonio
Francesco D'Antonio

1 September 2022 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
NFN. Fratelli
N. Fratelli
FPFederico Prefumo
Federico Prefumo
CMC. Maggi
C. Maggi
CCC. Cavalli
C. Cavalli
ASA. Sciarrone
A. Sciarrone
TGthe ADoPAD (Antenatal Diagnosis of Placental Adhesion Disorders) Working Group
the ADoPAD (Antenatal Diagnosis of Placental Adhesion Disorders) Working Group
Objective: To evaluate the performance of third‐trimester ultrasound for the diagnosis of clinically significant placenta accreta spectrum disorder (PAS) in women with low‐lying placenta or placenta previa.Methods: This was a prospective multicenter study of pregnant women aged ≥ 18 years who were diagnosed with low‐lying placenta (< 20 mm from the internal cervical os) or placenta previa (covering the internal cervical os) on ultrasound at ≥ 26 + 0 weeks' gestation, between October 2014 and January 2019. Ultrasound suspicion of PAS was raised in the presence of at least one of these signs on grayscale ultrasound: (1) obliteration of the hypoechogenic space between the uterus and the placenta; (2) interruption of the hyperechogenic interface between the uterine serosa and the bladder wall; (3) abnormal placental lacunae. Histopathological examinations were performed according to a predefined protocol, with pathologists blinded to the ultrasound findings. To assess the ability of ultrasound to detect clinically significant PAS, a composite outcome comprising the need for active management at delivery and histopathological confirmation of PAS was considered the reference standard. PAS was considered to be clinically significant if, in addition to histological confirmation, at least one of these procedures was carried out after delivery: use of hemostatic intrauterine balloon, compressive uterine suture, peripartum hysterectomy, uterine/hypogastric artery ligation or uterine artery embolization. The diagnostic performance of each ultrasound sign for clinically significant PAS was evaluated in all women and in the subgroup who had at least one previous Cesarean section and anterior placenta. Post‐test probability was assessed using Fagan nomograms.Results: A total of 568 women underwent transabdominal and transvaginal ultrasound examinations during the study period. Of these, 95 delivered in local hospitals, and placental pathology according to the study protocol was therefore not available. Among the 473 women for whom placental pathology was available, clinically significant PAS was diagnosed in 99 (21%), comprising 36 cases of placenta accreta, 19 of placenta increta and 44 of placenta percreta. The median gestational age at the time of ultrasound assessment was 31.4 (interquartile range, 28.6–34.4) weeks. A normal hypoechogenic space between the uterus and the placenta reduced the post‐test probability of clinically significant PAS from 21% to 5% in women with low‐lying placenta or placenta previa in the third trimester of pregnancy and from 62% to 9% in the subgroup with previous Cesarean section and anterior placenta. The absence of placental lacunae reduced the post‐test probability of clinically significant PAS from 21% to 9% in women with low‐lying placenta or placenta previa in the third trimester of pregnancy and from 62% to 36% in the subgroup with previous Cesarean section and anterior placenta. When abnormal placental lacunae were seen on ultrasound, the post‐test probability of clinically significant PAS increased from 21% to 59% in the whole cohort and from 62% to 78% in the subgroup with previous Cesarean section and anterior placenta. An interrupted hyperechogenic interface between the uterine serosa and bladder wall increased the post‐test probability for clinically significant PAS from 21% to 85% in women with low‐lying placenta or placenta previa and from 62% to 88% in the subgroup with previous Cesarean section and anterior placenta. When all three sonographic markers were present, the post‐test probability for clinically significant PAS increased from 21% to 89% in the whole cohort and from 62% to 92% in the subgroup with previous Cesarean section and anterior placenta.Conclusions: Grayscale ultrasound has good diagnostic performance to identify pregnancies at low risk of PAS in a high‐risk population of women with low‐lying placenta or placenta previa. Ultrasound may be safely used to guide management decisions and concentrate resources on patients with higher risk of clinically significant PAS. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.